In:
International Journal of Cancer, Wiley, Vol. 145, No. 3 ( 2019-08), p. 857-868
Abstract:
What's new? While the addition of bevacizumab to neoadjuvant therapy can improve rates of pathological complete response (pCR) in different malignancies, a biomarker to identify patients likely to benefit from the combined therapy is lacking. In this study, serum soluble carbonic anhydrase IX (sCAIX) was identified as a marker for the selection of patients with early breast cancer responding to combined bevacizumab and neoadjuvant chemotherapy. Significant improvements in pCR rates were observed in patients with low sCAIX levels. The addition of bevacizumab further improved 5‐year disease‐free survival in low sCAIX patients, while having detrimental effects in patients with high sCAIX levels.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink